SecBot SecBot
Biotech Drug Report Generated Jul 9, 2026

NX-1607

NRIX·Nurix Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
Time to market
Unknown, still in Phase 1a dose-escalation with no Phase 2/3 timelines set. If successful through Phase 1b, a registrational path would be several years away.
Why 4/10
NX-1607 is still in Phase 1a dose-escalation (enrollment complete as of Q2 2026); there is no scheduled PDUFA, registrational readout, or any hard dated binary catalyst within the next ~12 months. The company is "reviewing data to determine next steps." Per the rubric, a mid-stage drug with no imminent binary catalyst scores 3-5; combined with the fact that NX-1607 is not Nurix's lead asset (bexobrutideg is, partnered with Roche), this caps the score at 4.
Actionable Insight NEUTRAL

NX-1607 is an early-stage, first-in-class asset that is not the primary value driver for NRIX (that's bexobrutideg, which Roche partnered for up to $2.3B). Phase 1a data showing 49.3% DCR is encouraging but too early for pivotal conclusions. Watch for when the company announces Phase 1b expansion plans or presents updated data at a medical conference, no specific date is set. For now, NX-1607 is a pipeline free option on a novel immuno-oncology mechanism, not a standalone reason to trade NRIX.

Price Chart

Loading chart...

Executive Summary

NX-1607 is Nurix Therapeutics' first-in-class oral CBL-B inhibitor, a novel immuno-oncology agent that reactivates T cells and NK cells by releasing an intracellular immune brake. Phase 1a data (ESMO 2025) showed a 49.3% disease control rate in 82 heavily pretreated patients across 11 solid tumor types, including a confirmed partial response in a patient with MSS colorectal cancer (a notoriously immunotherapy-resistant tumor) who stayed on treatment for 27 months. As of Q2 2026, Phase 1a dose escalation enrollment is complete and the company is reviewing data to determine next steps. NX-1607 is not Nurix's lead asset, that distinction belongs to bexobrutideg (a BTK degrader partnered with Roche for up to $2.3B). The stock is driven primarily by the bexobrutideg story. NX-1607 is an early-stage pipeline component with encouraging but non-pivotal data and no imminent binary catalyst.

How It Works

NX-1607 is an oral pill that works as an "intramolecular glue", it locks a protein called CBL-B into a closed, inactive shape. CBL-B acts as a brake on the immune system's T cells and NK cells (the body's cancer-fighting infantry). By releasing this brake, NX-1607 reactivates immune cells to attack tumors. It's a novel approach to immunotherapy, rather than blocking PD-1/PD-L1 like Keytruda, it targets a different immune checkpoint inside the cell. Preclinical studies show it can reverse T-cell exhaustion and work both alone and with PD-1 inhibitors.

Trial Status

As of July 9, 2026 (Q2 2026 earnings), Nurix has completed enrollment of the current Phase 1a dose escalation cohorts of NX-1607 across multiple solid tumor types and is reviewing the data to determine next steps. The Phase 1a portion (NCT05107674) enrolled 82 patients across 11 tumor types with 6 once-daily and 5 twice-daily dosing regimens (5-80 mg total daily dose). Phase 1b expansion in select tumor types (including DLBCL) is planned but not yet initiated. Data was presented at ESMO 2025 and SITC 2025.

The Two-Sided Case

▲ Bull Case5
First-in-class CBL-B inhibitor with a novel mechanism (intramolecular glue) that differentiates it from PD-1/PD-L1 checkpoint inhibitors and could address immunotherapy-resistant tumors.
Phase 1a data showed a 49.3% disease control rate in 82 heavily pretreated patients, with a confirmed partial response in MSS CRC (micro-satellite stable colorectal cancer), a tumor type that typically does not respond to checkpoint inhibitors, with one patient treated for 27 months.
No other CBL-B inhibitor has advanced further in clinical trials globally (HotSpot Therapeutics' HST-1011 is also Phase 1), positioning NX-1607 as a potential first-mover if it advances.
Nurix has deep-pocketed validation from its Roche (bexobrutideg), Sanofi, Gilead, and Pfizer partnerships, providing financial stability and platform credibility.
Analyst consensus on NRIX is Strong Buy (20 Buy/Strong Buy vs 2 Hold, 0 Sell) with a mean price target of ~$31.44, implying roughly 27% upside from recent ~$24.31 levels.
▼ Bear Case5
NX-1607 is still in very early-stage Phase 1a with no Phase 1b expansion initiated yet, the drug is years from any potential approval and has no guarantee of advancing past Phase 1.
No hard, dated catalyst exists for NX-1607 in the next ~12 months. The company is simply 'reviewing data to determine next steps,' creating an indefinite timeline.
NX-1607 is not Nurix's primary value driver, the stock is overwhelmingly driven by the Roche-partnered bexobrutideg (BTK degrader) story, so NX-1607 developments may have limited impact on share price.
Competition exists: HotSpot Therapeutics has HST-1011, another Phase 1 CBL-B inhibitor that presented clinical data at ESMO 2024. Other companies (Orum Therapeutics, various pharmas) have preclinical CBL-B programs.
Phase 1a data, while encouraging, showed a 49.3% DCR with only 1 confirmed partial response, typical early signal in a heavily pretreated population, not yet proof of transformative efficacy.

Upcoming Catalysts

  • Announcement of Phase 1b expansion plans and dose selection (timing uncertain, company is 'reviewing data to determine next steps')
  • Potential updated NX-1607 data presentation at a future medical conference (no specific conference announced)
  • Any corporate update on next development steps for NX-1607 in future earnings calls

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Nurix Therapeutics, Inc. PRESS-RELEASE NRIX ·Originating report

Sources · 10

Hover a chip for the title
1 markets.financialcontent.com2 ir.nurixtx.com3 clinicaltrials.gov4 ir.nurixtx.com5 biospace.com6 nurixtx.com7 synapse.patsnap.com8 globenewswire.com9 nurixtx.com10 ashpublications.org